Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial

被引：12

作者：

Friedlander, Michael

Gebski, Val

Gibbs, Emma

Bloomfield, Ralph

Hilpert, Felix

Wenzel, Lari B.

Joly, Florence

Eek, Daniel

Rodrigues, Manuel

Clamp, Andrew R.

Penson, Richard T.

Provencher, Diane M.

Korach, Jacob

Huzarski, Tomasz

Vidal, Laura

Salutari, Vanda

Scott, Clare L.

Nicoletto, Maria Ornella

Tamura, Kenji

Pujade-Lauraine, Eric

机构：

[1] Prince Wales Hosp, UNSW Clin Sch, Randwick, NSW, Australia

[2] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia

[3] AstraZeneca, Cambridge, England

[4] AGO, Hamburg, Germany

[5] Krankenhaus Jerusalem Hamburg, Hamburg, Germany

[6] Univ Calif Irvine, Irvine, CA USA

[7] GINECO, Caen, France

[8] Reg Ctr Control Canc Francois Baclesse, Caen, France

[9] AstraZeneca, Gothenburg, Sweden

[10] Inst Curie, Paris, France

[11] Christie NHS Fdn Trust, Manchester, Lancs, England

[12] Univ Manchester, Manchester, Lancs, England

[13] Harvard Med Sch, Boston, MA 02115 USA

[14] Univ Montreal, Montreal, PQ, Canada

[15] Tel Aviv Univ, Sheba Med Ctr, Tel Hashomer, Israel

[16] Pomeranian Med Univ, Szczecin, Poland

[17] Hosp Clin Barcelona, Barcelona, Spain

[18] Policlin Univ Gemelli, Rome, Italy

[19] Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia

[20] Inst Oncol Veneto, Padua, Italy

[21] Natl Canc Ctr Hosp East, Dept Breast & Med Oncol, Tokyo, Japan

[22] Univ Paris 05, AP HP, Paris, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.5507

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5507

引用

页数：6

共 28 条

[1] Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer: SOLO2 Phase III
Hasenburg, A.
Harter, P.
Park-Simon, T-W.
Gropp-Meier, M.
Heitz, F.
Soergel, P.
Ataseven, B.
Friedlaender, M.
Hilpert, F.
Pujade-Lauraine, E.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 88 - 89
[2] HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND PATIENT-CENTRED OUTCOMES WITH OLAPARIB MAINTENANCE POST-CHEMOTHERAPY IN PATIENTS WITH GERMLINE BRCA-MUTATED PLATINUM-SENSITIVE RELAPSED SEROUS OVARIAN CANCER (PSR SOC)
Friedlander, M.
Gebski, V.
Gibbs, E.
Bloomfield, R.
Hilpert, F.
Wenzel, L. B.
Joly, F.
Eek, D.
Rodrigues, M.
Clamp, A.
Penson, R.
Provencher, D.
Korach, J.
Huzarski, T.
Vidal, L.
Salutari, V.
Scott, C.
Nicoletto, M. O.
Tamura, K.
Pujade-Lauraine, E.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1941 - 1941
[3] Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): Phase III SOLO2 trial
Ledermann, Jonathan A.
Lortholary, Alain
Penson, Richard T.
Gibbs, Emma
Provencher, Diane M.
Bruchim, Ilan
Huzarski, Tomas
Barretina-Ginesta, Maria Pilar
Sabbatini, Roberto
Mileshkin, Linda R.
Colombo, Nicoletta
Park-Simon, Tjoung-Won
Matsumoto, Koji
Sonke, Gabe S.
Mikheeva, Olga N.
Kim, Jae-Weon
Girotto, Gustavo Colagiovanni
Denys, Hannelore
Lowe, Elizabeth S.
Pujade-Lauraine, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[4] OLAPARIB MONOTHERAPY VERSUS (VS) CHEMOTHERAPY FOR GERMLINE BRCA-MUTATED (GBRCAM) PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER (PSR OC) PATIENTS (PTS): PHASE III SOLO3 TRIAL
Penson, R. T.
Valencia, R. V.
Cibula, D.
Colombo, N.
Ill, C. L.
Bidzinski, M.
Kim, J. W.
Nam, J. H.
Madry, R.
Hernandez, C. H.
Mora, P.
Ryu, S. Y.
Milenkova, T.
Lowe, E.
Barker, L.
Scambia, G.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A21 - A21
[5] Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.
Penson, Richard T.
Valencia, Ricardo Villalobos
Cibula, David
Colombo, Nicoletta
Leath, Charles A.
Bidzinski, Mariusz
Kim, Jae-Weon
Nam, Joo-Hyun
Madry, Radoslaw
Hernandez, Carlos Hernandez
Mora, Paulo Alexandre Ribeiro
Ryu, Sang Young
Milenkova, Tsveta
Lowe, Elizabeth S.
Barker, Laura
Scambia, Giovanni
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[6] Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy
Tjokrowidjaja, Angelina
Lee, Chee K.
Friedlander, Michael
Gebski, Val
Gladieff, Laurence
Ledermann, Jonathan
Penson, Richard
Oza, Amit
Korach, Jacob
Huzarski, Tomasz
Manso, Luis
Pisano, Carmela
Asher, Rebecca
Lord, Sarah J.
Kim, Se Ik
Lee, Jung-Yun
Colombo, Nicoletta
Park-Simon, Tjoung-Won
Fujiwara, Keiichi
Sonke, Gabe
Vergote, Ignace
Kim, Jae-Weon
Pujade-Lauraine, Eric
EUROPEAN JOURNAL OF CANCER, 2020, 139 : 59 - 67
[7] Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial
Liu, Jihong
Yin, Rutie
Wu, Lingying
Zhu, Jianqing
Lou, Ge
Wu, Xiaohua
Zhou, Qi
Gao, Yunong
Kong, Beihua
Lu, Xin
Wang, Jing
Chen, Youguo
Cheng, Ying
Wang, Yueling
Lu, Weiguo
Li, Wei
Ma, Xin
Hsu, Kate
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (06) : 714 - 722
[8] Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): Phase III SOLO2 trial
Korach, J.
Freyer, G.
Banerjee, S.
Asher, R.
Cosin, J.
Oza, A. M.
Poveda, A. M.
Di Napoli, M.
Scott, C.
Lapresa, M.
Heitz, F.
Takehara, K.
Sonke, G. S.
Tjulandin, S.
Kim, J-W.
Hegg, R.
Vergote, I. B.
Turner, S.
Pujade-Lauraine, E.
ANNALS OF ONCOLOGY, 2018, 29
[9] Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial
Friedlander, Michael
Gebski, Val
Gibbs, Emma
Davies, Lucy
Bloomfield, Ralph
Hilpert, Felix
Wenzel, Lari B.
Eek, Daniel
Rodrigues, Manuel
Clamp, Andrew
Penson, Richard T.
Provencher, Diane
Korach, Jacob
Huzarski, Tomasz
Vidal, Laura
Salutari, Vanda
Scott, Clare
Nicoletto, Maria Ornella
Tamura, Kenji
Espinoza, David
Joly, Florence
Pujade-Lauraine, Eric
LANCET ONCOLOGY, 2018, 19 (08): : 1126 - 1134
[10] Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
Penson, Richard T.
Villalobos Valencia, Ricardo
Cibula, David
Colombo, Nicoletta
Leath, Charles A., III
Bidzinski, Mariusz
Kim, Jae-Weon
Nam, Joo Hyun
Madry, Radoslaw
Hernandez, Carlos
Mora, Paulo A. R.
Ryu, Sang Young
Milenkova, Tsveta
Lowe, Elizabeth S.
Barker, Laura
Scambia, Giovanni
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (11) : 1164 - +

← 1 2 3 →